Key result
Implantation of ultra-long (44 mm/48 mm) Supraflex sirolimus-eluting stents in complex, long coronary artery lesions resulted in 99.3% of patients remaining free from MACE at one year.
Why the study?
The study was conducted to assess the safety and clinical outcomes of ultra-long (44 mm/48 mm) biodegradable polymer-coated Supraflex sirolimus-eluting stents in real-world patients with complex, long coronary artery lesions.
Observational (n=141)
No
Ultra-long (44 mm/48 mm) sirolimus-eluting stents demonstrated high safety and efficacy at one year in real-world patients with complex, long coronary artery lesions.
May support ultra-long stent use in complex lesions; leaves open need for randomized confirmation.
BACKGROUND: The FLEX-LONG study assessed the safety and clinical outcomes of ultra-long (44 mm/48 mm) biodegradable polymer-coated Supraflex (Sahajanand Medical Technology Pvt. Ltd., Surat, India) sirolimus-eluting stents (SES) in real-world patients with complex, long coronary artery lesions. METHODS: It was an investigator-initiated, retrospective, non-randomized, observational and single-center study, which evaluated one-year results of 141 patients who had undergone implantation of at least one ultra-long (44 mm/48 mm) Supraflex SES. The incidence of major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR), at one-year follow-up was considered as primary outcome. Stent thrombosis was analyzed as a safety outcome. RESULTS: The mean age of the study population was 56.2±9.6 years and 78.0% (110/141) patients were male. The study analyzed high risk patients, including 62 (44.0%) hypertensive and 60 (42.6%) diabetic patients. Total 147 target lesions were treated, including 25 (17.0%) total occlusions. Total 51 (34.7%) and 96 (65.3%) Supraflex SES of 44 mm and 48 mm were implanted, respectively. Average stent length and diameter were 46.6±1.9 mm and 3.4±0.2 mm, respectively. One-year follow-up was obtained in 100% of patients. There was one probable stent thrombosis after three weeks. At one-year follow-up, 99.3% of patients remained event free. CONCLUSIONS: The results of the FLEX-LONG study support the use of ultra-long (44 mm/48 mm) Supraflex SES, in the treatment of high-risk real-world patients. The stent appeared to be safe and effective at one-year with low clinical events in complex, long coronary artery lesions.
No takes yet. Share an insight, caveat, or question.
Pamidimukkala et al. (2020) conducted an observational in complex, long coronary artery lesions (n=141). ultra-long Supraflex sirolimus-eluting stents was evaluated on major adverse cardiac events (MACE), a composite of cardiac death, myocardial infarction (MI) and target lesion revascularization (TLR). Implantation of ultra-long (44 mm/48 mm) Supraflex sirolimus-eluting stents in complex, long coronary artery lesions resulted in 99.3% of patients remaining free from MACE at one year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: